Corporate Overview
Founded in 1993, 3SBio Inc. (hereinafter referred to as “3SBio”) is a China-rooted, globally engaged high-tech enterprise dedicated to the R&D, manufacturing, and commercialization of innovative biologics.
The company was listed on the Main Board of the Hong Kong Stock Exchange (01530.HK) in June 2015, marking one of the largest biopharmaceutical IPOs globally that year. Its subsidiary, Sunshine Guojian, went public on the STAR Market of the Shanghai Stock Exchange (688336.SH) in July 2020. The dual-listing platforms work in synergy to accelerate the development and delivery of innovative biologics while broadening patient access. In 2025, 3SBio reported operating revenue of RMB 17.7 billion and garnered recognition as one of the Top 100 Pharmaceutical Enterprises in China for the 11th consecutive year.
Independent Innovation contributing to Continuously Enhanced Industrialization Capabilities
Since its inception, 3SBio has remained focused on addressing unmet clinical needs while advancing high-quality development through independent innovation. In 1998, our core product EPIAO® (Recombinant Human Erythropoietin Injection, rhEPO) was approved for marketing, ending China's long-standing dependence on imported drugs for the treatment of renal anemia and enabling self-sufficiency in biologics in this critical therapeutic area. In 2005, TPIAO® (Recombinant Human Thrombopoietin Injection, rhTPO) was approved for marketing, becoming the world's first commercially available recombinant human thrombopoietin. These two landmark innovations were successively included in China’s National “863 Program” and major science and technology projects. They have been recommended by nearly 100 authoritative clinical guidelines both domestically and internationally, and have benefited millions of patients, reflecting the continued advancement of China’s independent biopharmaceutical innovation capabilities.
R&D-Driven Continuous Innovation
Building on our integrated innovation capabilities, we have established a multi-site, end-to-end biologics R&D platform across six specialized R&D bases and secured over 190 granted national invention patents. Our dedicated R&D team of more than 840 professionals — over half of whom hold a master’s degree or higher — forms a high-caliber, multidisciplinary talent pool powering our innovation pipeline.
We implement a phased R&D strategy of “commercializing one generation, securing approvals for the next, advancing research on the subsequent one, and laying the groundwork for the one beyond.” We currently have nearly 40 commercialized products and 25 innovative therapies in our R&D pipeline, covering nephrology, hematology, oncology, autoimmunity, and dermatology. Over the past decade, we have invested more than RMB 7.6 billion in R&D, harnessing relentless innovation to expand affordable, patient-wide access to our biologic therapies.
R&D Base
Layout of 6 specialized R&D bases
R&D Team
The company has established a professional R&D team consisting of over 840 members
Invention Patent
Possessing over 190 authorized national invention patents
Aligned with International Standards, Anchored in Superior Quality
Innovative biologics, characterized by complex structures and exacting manufacturing processes, require exceptionally stringent quality standards. At 3SBio, we benchmark against the highest international standards, embed rigorous quality control throughout the entire product lifecycle, and uphold a “zero-defect” quality culture. Our manufacturing facilities have secured internationally recognized GMP certifications from regulatory bodies including China’s NMPA, the European Union, PIC/S, and the U.S. FDA. We have established an internal control system that surpasses industry standards as well as a 24/7 pharmaceutical safety monitoring mechanism. Backed by four major biologics manufacturing bases alongside four specialized CDMO facilities, we have built scalable, standardized, and internationally aligned manufacturing capacity—giving us a strong competitive edge in the global supply of our proprietary products and cross-border industrialization partnerships.
Deep Local Roots and Global Footprint
On the domestic front, 3SBio has continuously expanded a nationwide supply network reaching down to the grassroots level, with our products available across medical institutions at all levels and our core offerings included in the National Reimbursement Drug List (NRDL). To date, we have brought our therapies to more than 7 million patients in China — bridging the last mile in delivering high-quality innovative biologics to grassroots communities.
On the global front, 3SBio entered into a global strategic partnership with Pfizer in 2025 for SSGJ-707, our proprietary PD-1/VEGF bispecific antibody, in a deal worth over US$6 billion, including an upfront payment of US$1.4 billion and a US$100 million equity investment. This milestone signifies 3SBio's evolution beyond product exports into a new era of technology and standards exportation. Today, our core products are marketed in more than 39 countries and regions, as our global footprint continues to expand.
ESG Governance and Sustainable Development
At 3SBio, we remain committed to sustainable development. We have published dedicated ESG reports for ten consecutive years, placing us among China’s earliest biopharmaceutical companies to issue ESG reports. Our ESG performance has been widely recognized: we have maintained an AA rating from MSCI ESG, received an AA rating from Wind ESG in 2026, and achieved a B rating from CDP Climate Change for six consecutive years. Through public welfare initiatives such as the Ankylosing Spondylitis Healthy Villages Program, we have continuously extended high-quality medical resources to grassroots communities, while building the capacity of grassroots healthcare professionals and bringing innovative biologics to broader patient populations.
Guided by our founding mission — "making innovative biologics accessible," we will adhere to principled innovation, while continuously elevating world-class quality standards, driving breakthroughs in cutting-edge technologies, and improving medicine accessibility. Rooted in China and oriented towards the world, we aim to build 3SBio into a world-leading biopharmaceutical enterprise.
